Carolina Ponce Orellana, MD
Cardiovascular Disease · Albuquerque, NMNPI 1366754889
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (55.9%), travel and lodging and speaking fees — rather than concentrated in one kind of arrangement. 25 manufacturers reported payments, led by Abiomed at 33.0% of the total. Reporting peaked in 2022 at $3,247 and has fallen 78.5% since, to $697 in 2025. Among cardiovascular disease clinicians in NM with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 208 payments — averaging $56.16 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Abiomed$4K
- Medtronic$3K
- Edwards Lifesciences$2K
- Abbott$1K
- Novartis$441
- Chiesi USA, Inc.$283
- plus $2K from 19 others
What the payments were for
- Speaking & faculty fees$8007%
- Grants$270%
- Travel & lodging$4,19936%
- Food & beverage$6,53456%
- Education$1211%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Abiomed | 30 | $3,855 |
| Medtronic(2 entities) | 37 | $2,625 |
| Edwards Lifesciences | 13 | $1,779 |
| Abbott | 46 | $1,199 |
| Novartis | 11 | $441 |
| Chiesi USA, Inc. | 18 | $283 |
| Boston Scientific | 7 | $252 |
| E.r. Squibb & Sons, L.L.C. | 6 | $191 |
| Amgen | 4 | $165 |
| Atricure, Inc. | 1 | $109 |
| Cvrx, Inc. | 1 | $106 |
| Cardiovascular Systems Inc. | 2 | $104 |
| Philips North America LLC | 5 | $103 |
| Shockwave Medical, Inc | 5 | $90 |
| Boehringer Ingelheim | 4 | $65 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 4 | $52 |
| Terumo Medical Corporation | 1 | $48 |
| Livanova USA, Inc. | 2 | $40 |
| Esperion Therapeutics, Inc. | 2 | $35 |
| Pfizer | 2 | $32 |
| AstraZeneca | 2 | $29 |
| Cook Medical LLC | 2 | $27 |
| Amarin Pharma, Inc. | 1 | $25 |
| Johnson & Johnson | 1 | $17 |
| Regeneron Healthcare Solutions, Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Impella$2,789
- COREVALVE EVOLUT R$1,668
- Edwards SAPIEN 3 Transcatheter Heart Valve$1,090
- Edwards SAPIEN 3 Ultra Transcatheter Heart Valve$392
- LEQVIO$265
- Micra$121
- Diamondback Coronary$119
- Repatha$117
- EPI-SENSE GUIDED COAGULATION SYS$109
- ATRICURE ATRICLIP LAA EXCLUSION$109
- Barostim Neo System$106
- CoreValve Evolut$100
How this compares
$11,681 in reported general payments places this provider in the 90th percentile of 101 cardiovascular disease providers in New Mexico.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 11 | $14,095 |
| Carvedilol | 23 | $284 |
| Ezetimibe | 12 | $280 |
| Losartan Potassium | 21 | $271 |
| Atorvastatin Calcium | 15 | $194 |
| Metoprolol Succinate | 17 | $177 |
| Rosuvastatin Calcium | 14 | $170 |
| Amlodipine Besylate | 14 | $148 |
| Furosemide | 11 | $101 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $32 | $14,09511 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 101 cardiovascular disease providers in New Mexico.
Other cardiovascular disease in Albuquerque
- Abinash AchrekarAlbuquerque$88K
- Adam BanksAlbuquerque$38K
- Stacey CleggAlbuquerque$21K
- Leonardo MaciasAlbuquerque$15K
- Phillip CampAlbuquerque$11K
- Warren LaskeyAlbuquerque$10K
- Kayvan ElliniAlbuquerque$10K
- Bilal AlqamAlbuquerque$8K
- Daniel FriedmanAlbuquerque$6K
- Robert TaylorAlbuquerque$6K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.